www.fdanews.com/articles/196715-sinovac-begins-phase-1-trial-of-its-covid-19-vaccine-candidate
Sinovac Begins Phase 1 Trial of its COVID-19 Vaccine Candidate
April 20, 2020
Sinovac Biotech has begun a phase 1 trial in China to evaluate the safety of a potential COVID-19 vaccine.
The trial in 144 healthy adults will evaluate Sinovac’s chemically inactivated coronavirus vaccine with Dynavax’s CpG 1018 adjuvant.
Dynavax developed the adjuvant to boost the immune response to its approved hepatitis B vaccine HEPLISAV-B.